Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

APTO opened at $0.40 on Tuesday. The company has a fifty day moving average price of $0.38 and a two-hundred day moving average price of $0.68. The firm has a market capitalization of $7.20 million, a PE ratio of -0.09 and a beta of 1.26. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.